Enspryng Europska Unija - hrvatski - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

ENSPRYNG 120 mg/1 mL otopina za injekciju u napunjenoj štrcaljki Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

enspryng 120 mg/1 ml otopina za injekciju u napunjenoj štrcaljki

roche d.o.o.roche ltd. - satralizumab - otopina za injekciju u napunjenoj štrcaljki - 120 mg/1 ml - 1 ml otopine za injekciju sadrži 120 mg satralizumaba

Tyruko Europska Unija - hrvatski - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Tysabri Europska Unija - hrvatski - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

TYSABRI 300 mg/15 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tysabri 300 mg/15 ml koncentrat za rastvor za infuziju

medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba

Dimethyl fumarate Neuraxpharm Europska Unija - hrvatski - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Fingolimod Medochemie 0,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fingolimod medochemie 0,5 mg tvrde kapsule

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - fingolimodklorid - kapsula, tvrda - 0,5 mg - urbroj: svaka kapsula sadrži 0,5 mg fingolimoda (u obliku fingolimodklorida)

Fingolimod Stada 0,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fingolimod stada 0,5 mg tvrde kapsule

stada d.o.o., hercegovačka 14, zagreb, hrvatska - fingolimodklorid - kapsula, tvrda - 0,5 mg - urbroj: jedna kapsula sadrži 0,5 mg fingolimoda (u obliku fingolimodklorida)

Efigalo 0,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

efigalo 0,5 mg tvrde kapsule

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - fingolimodklorid - kapsula, tvrda - 0,5 mg - urbroj: jedna tvrda kapsula sadrži fingolimodklorid što odgovara 0,5 mg fingolimoda

FINGOLIMOD TEVA 0,25 mg/1 kapsula kapsula, tvrda Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

fingolimod teva 0,25 mg/1 kapsula kapsula, tvrda

pliva d.o.o.sarajevo - финголимод - kapsula, tvrda - 0,25 mg/1 kapsula - jedna kapsula, tvrda sadrži: 0,25 mg fingolimoda (u obliku fingolimod hidrohlorida)